COX-2与p53在非小细胞肺癌中的表达及临床意义  

Expressions of COX-2 and p53 in Patients with Non-small Cell Lung Cancer and Their Significance

作　　者：王志刚[1] 周彩存[2] 欧阳永娥[1] 陈伟文[1] 叶晓艺[1] 

机构地区：[1]福建省泉州市第一医院,福建泉州362000 [2]上海市肺科医院,上海200433

出　　处：《中国肿瘤》2007年第1期47-50,共4页China Cancer

摘　　要：[目的]探讨COX-2和p53蛋白在非小细胞肺癌(NSCLC)中的表达和临床意义。[方法]采用免疫组织化学法检测60例NSCLC组织中COX-2与p53蛋白的表达情况。[结果]COX-2与p53蛋白在NSCLC中阳性表达率分别为56.67%和61.67%。COX-2的表达水平与肺癌的病理类型相关(P=0.009)。COX-2阳性表达的Ⅲ期NSCLC患者中位生存期(MST)和3年生存率均显著低于COX-2阴性表达患者;但p53阳性、阴性表达患者MST和3年生存率无显著性差异。Cox逐步回归分析显示,TNM分期和肿瘤组织COX-2表达水平是NSCLC预后独立因素。[结论]COX-2的高表达与NSCLC患者预后不良相关。[Purpose] To investigate the expressions of eyelooxygenase 2（COX-2） and p53 in the patients with non-small cell lung cancer （NSCLC） and their clinical significance. [Methods ] The expressions of COX-2 and p53 were detected with immunohistoehemieal staining in 60 eases of NSCLC. [Results] The expressions of COX-2 and p53 in NSCLC were 56.67% and 61.67%, respectively. The expression of COX-2 was correlated with pathological types （P=0.009）. Median sur- vival time（MST） and 3-year survival in stage Ⅲ patients with positive COX-2 expression were significantly lower than those with negative COX-2 expression, but median survival time and 3-year survival were not significantly different between the patients with positive or negative p53 expression. The Cox-regression analysis showed that TNM staging nostic factors in patients with NSCLC. [Conclusions] and COX-2 expression were independent progHigh expression of COX-2 is related with poor prognosis in NSCLC.

关 键 词：非小细胞肺癌 免疫组织化学 COX-2 P53 预后 

分 类 号：R734.2[医药卫生—肿瘤]